[The relative therapeutic value of drugs in international comparison: differences between Switzerland and Canada].
In Switzerland the relative therapeutic value of various drugs (e.g. pyrazolone analgesics, phenacetin, clindamycine, clioquinol) is placed demonstrably higher than in Canada. In Canada, rare but possibly dangerous complications of drug therapy are considered to be of greater importance. Two factors might be responsible for these differences: 1. Compared with similar publications in Canada, drug advertisements in Swiss medical journals contain fewer warnings of untoward effects. This can be interpreted as an "information lag". 2. Since the link between an untoward effect and a drug is very difficult to establish with absolute certainty, it may be concluded that the drug is relatively inoffensive. This conclusion is drawn more often in Switzerland than in Canada. Uniformization of the way in which the physician is presented with information concerning untoward drug effects would be an important step towards the establishment of internationally accepted standards of drug therapeutic value.
D000700:Analgesics / Q000009:adverse effects; D002170:Canada; D002981:Clindamycin / Q000009:adverse effects; D004345:Drug Industry; D064420:Drug-Related Side Effects and Adverse Reactions; D004761:Enterocolitis, Pseudomembranous / Q000139:chemically induced; D006912:Hydroxyquinolines / Q000009:adverse effects; D013557:Switzerland; D013810:Therapeutic Equivalency
D000700:Analgesics; D006912:Hydroxyquinolines; D002981:Clindamycin
Der relative therapeutische Wert von Medikamenten im internationalen Vergleich: Unterschiede zwischen der Schweiz und Kanada